A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs CK 2127107 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms FORTITUDE-ALS
- Sponsors Cytokinetics
- 27 Jul 2017 Status changed from not yet recruiting to recruiting, according to a Cytokinetics media release.
- 24 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 17 May 2017 Status changed from planning to not yet recruiting.